Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MGTX Stock Forecast 2025-2026
$6.48
Current Price
$520.77M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MGTX Price Targets
+671.6%
To High Target of $50.00
+309.0%
To Median Target of $26.50
+100.6%
To Low Target of $13.00
MGTX Price Momentum
-2.3%
1 Week Change
+17.8%
1 Month Change
+50.3%
1 Year Change
+6.4%
Year-to-Date Change
-25.9%
From 52W High of $8.75
+68.3%
From 52W Low of $3.85
📊 TOP ANALYST CALLS
Did MGTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if MeiraGTx is one of their latest high-conviction picks.
Latest MGTX Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, MGTX has a bullish consensus with a median price target of $26.50 (ranging from $13.00 to $50.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $6.48, the median forecast implies a 309.0% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 100.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MGTX Analyst Ratings
6
Buy
0
Hold
0
Sell
MGTX Price Target Range
Low
$13.00
Average
$26.50
High
$50.00
Current: $6.48
Latest MGTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MGTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 14, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $35.00 |
| Mar 17, 2025 | RBC Capital | Luca Issi | Outperform | Maintains | $13.00 |
| Feb 24, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Nov 18, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Nov 14, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $11.00 |
| Aug 13, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $9.00 |
| Jul 31, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $36.00 |
| Mar 15, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $11.00 |
| Aug 11, 2023 | Chardan Capital | Geulah Livshits | Buy | Reiterates | $41.00 |
| Aug 11, 2023 | RBC Capital | Luca Issi | Outperform | Maintains | $11.00 |
| May 12, 2023 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $25.00 |
| Mar 16, 2023 | Chardan Capital | Geulah Livshits | Buy | Maintains | $41.00 |
| Mar 15, 2023 | RBC Capital | Luca Issi | Outperform | Maintains | $22.00 |
| Aug 12, 2022 | Chardan Capital | Geulah Livshits | Buy | Maintains | $47.00 |
| May 13, 2022 | Barclays | Gena Wang | Overweight | Maintains | $18.00 |
| May 13, 2022 | Chardan Capital | Geulah Livshits | Buy | Maintains | $46.00 |
| Oct 23, 2020 | RBC Capital | Outperform | Initiates | $0.00 | |
| Sep 3, 2019 | Piper Sandler | Overweight | Initiates | $0.00 | |
| Sep 3, 2019 | Piper Jaffray | Overweight | Initiates | $0.00 | |
| Jul 9, 2018 | Evercore ISI Group | Outperform | Initiates | $0.00 |
MeiraGTx Holdings plc (MGTX) Competitors
The following stocks are similar to MeiraGTx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MeiraGTx Holdings plc (MGTX) Financial Data
MeiraGTx Holdings plc has a market capitalization of $520.77M with a P/E ratio of -3.1x. The company generates $34.51M in trailing twelve-month revenue with a 28.5% profit margin.
Revenue growth is +176.3% quarter-over-quarter, while maintaining an operating margin of -2,159.7% and return on equity of -216.1%.
Valuation Metrics
Market Cap
$520.77M
Enterprise Value
$535.12M
P/E Ratio
-3.1x
PEG Ratio
7.8x
Price/Sales
15.1x
Growth & Margins
Revenue Growth (YoY)
+176.3%
Gross Margin
+28.5%
Operating Margin
-2,159.7%
Net Margin
+28.5%
EPS Growth
+176.3%
Financial Health
Cash/Price Ratio
+12.8%
Current Ratio
1.5x
Debt/Equity
244.4x
ROE
-216.1%
ROA
-37.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
MeiraGTx Holdings plc (MGTX) Business Model
About MeiraGTx Holdings plc
What They Do
Develops gene therapies for serious diseases.
Business Model
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company that aims to address unmet medical needs through innovative treatments. The company generates revenue by developing proprietary gene therapies targeting specific genetic disorders, particularly in ocular and neurodegenerative diseases, and advancing its clinical pipeline towards commercialization.
Additional Information
With a focus on industrial scalability and technological innovation, MeiraGTx has established strategic partnerships in manufacturing and research. This positions the company favorably within the biotechnology and pharmaceuticals sectors, enhancing its contributions to personalized medicine and the potential for significant medical advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
375
CEO
Dr. Alexandria Forbes Ph.D.
Country
United States
IPO Year
2018
Website
meiragtx.comMeiraGTx Holdings plc (MGTX) Latest News & Analysis
Latest News
Quick Summary
MeiraGTx announced a $200M collaboration with Hologen AI, forming Hologen Neuro AI Ltd to expedite AAV-GAD for Parkinson's. The FDA granted RMAT designation for this treatment and aligned on a Phase 2 study for RIX. Additionally, data for AIPL1-related retinal dystrophy showed positive results, with plans for MAA filing in the UK and discussions with the FDA.
Why It Matters
The collaboration with Hologen AI and FDA designations enhance MeiraGTx's pipeline, potentially accelerating revenue from innovative therapies, thereby impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings PLC (MGTX) reported a quarterly loss of $0.51 per share, worse than the expected loss of $0.38, but an improvement from a loss of $0.77 per share a year earlier.
Why It Matters
MeiraGTx's larger-than-expected quarterly loss may signal financial struggles, impacting investor confidence and stock performance. Year-over-year improvement could provide some optimism.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
MeiraGTx showcased its innovative gene and cell therapy technology at multiple poster presentations, emphasizing the depth and novelty of its platforms.
Why It Matters
MeiraGTx's advancements in gene and cell therapy could indicate strong future growth and innovation, potentially driving stock performance and attracting investment interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MeiraGTx Holdings received FDA RMAT designation for AAV-GAD as a one-time Parkinson's treatment, based on positive data from three clinical studies, enhancing regulatory advantages.
Why It Matters
The RMAT designation for AAV-GAD enhances its development prospects, potentially leading to accelerated approval and market entry, which could significantly boost MeiraGTx's stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The global cone rod dystrophy market is projected to grow from $131.29M in 2024 to $177.59M by 2030, at a CAGR of 5.33%, driven by gene therapies and personalized medicine. North America leads in market size.
Why It Matters
The projected growth of the cone rod dystrophy market signals investment opportunities, particularly in gene therapies and personalized medicine, driven by innovation and government support.
Source: GlobeNewsWire
Market Sentiment:
Neutral
MeiraGTx Holdings: Gaining Regulatory Focus
2 months ago
Quick Summary
MeiraGTx (MGTX) focuses on gene therapies for ocular diseases and Parkinson's, showing promising clinical results. The company has a strong cash position, enhanced by a $200M deal with Hologen.
Why It Matters
MeiraGTx's promising gene therapies, strong clinical data, and solid financial backing from a $200mn deal enhance its growth potential, making it an attractive option for investors.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About MGTX Stock
What is MeiraGTx Holdings plc's (MGTX) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, MeiraGTx Holdings plc (MGTX) has a median price target of $26.50. The highest price target is $50.00 and the lowest is $13.00.
Is MGTX stock a good investment in 2025?
According to current analyst ratings, MGTX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MGTX stock?
Wall Street analysts predict MGTX stock could reach $26.50 in the next 12 months. This represents a 309.0% increase from the current price of $6.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MeiraGTx Holdings plc's business model?
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company that aims to address unmet medical needs through innovative treatments. The company generates revenue by developing proprietary gene therapies targeting specific genetic disorders, particularly in ocular and neurodegenerative diseases, and advancing its clinical pipeline towards commercialization.
What is the highest forecasted price for MGTX MeiraGTx Holdings plc?
The highest price target for MGTX is $50.00 from at , which represents a 671.6% increase from the current price of $6.48.
What is the lowest forecasted price for MGTX MeiraGTx Holdings plc?
The lowest price target for MGTX is $13.00 from Luca Issi at RBC Capital, which represents a 100.6% increase from the current price of $6.48.
What is the overall MGTX consensus from analysts for MeiraGTx Holdings plc?
The overall analyst consensus for MGTX is bullish. Out of 6 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $26.50.
How accurate are MGTX stock price projections?
Stock price projections, including those for MeiraGTx Holdings plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 20, 2025 8:22 AM UTC